Page last updated: 2024-09-05

erlotinib hydrochloride and Weight Reduction

erlotinib hydrochloride has been researched along with Weight Reduction in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Kowalski, DM; Krawczyk, P; Krzakowski, M; Kucharczyk, T; Milanowski, J; Mlak, R; Wojas-Krawczyk, K	1

Other Studies

1 other study(ies) available for erlotinib hydrochloride and Weight Reduction

Article	Year
The applicability of a predictive index for second- and third-line treatment of unselected non-small-cell lung cancer patients. Respiration; international review of thoracic diseases, 2011, Volume: 82, Issue:4 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Eruptions; Erlotinib Hydrochloride; Exons; Female; Gene Expression Regulation, Neoplastic; Humans; Karnofsky Performance Status; Lipoproteins, HDL; Lung Neoplasms; Male; Middle Aged; Mutation; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Risk Factors; Sex Factors; Survival Analysis; Time Factors; Weight Loss	2011

Article

Year

The applicability of a predictive index for second- and third-line treatment of unselected non-small-cell lung cancer patients.

Respiration; international review of thoracic diseases, 2011, Volume: 82, Issue:4

Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Eruptions; Erlotinib Hydrochloride; Exons; Female; Gene Expression Regulation, Neoplastic; Humans; Karnofsky Performance Status; Lipoproteins, HDL; Lung Neoplasms; Male; Middle Aged; Mutation; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Risk Factors; Sex Factors; Survival Analysis; Time Factors; Weight Loss

2011